# Birth Defects Study To Evaluate Pregnancy exposureS (BD-STEPS)

Source: https://welltoldgrants.com/grants/rfa-dd-23-001-birth-defects-study-to-evaluate-pregnancy-exposures-bd/  
Official notice: https://www.grants.gov/search-results-detail/342111

> Centers for Disease Control and Prevention - ERA offered grants of up to $1.2 million (at least $100,000) to any type of organization. It expected to make about 10 awards worth $20.6 million in total. Applications closed on January 17, 2023.

| Field | Value |
|---|---|
| Opportunity number | RFA-DD-23-001 |
| Agency | Centers for Disease Control and Prevention - ERA |
| Status | Forecast |
| Deadline | January 17, 2023 |
| Award ceiling | $1.2 million |
| Award floor | $100,000 |
| Expected awards | 10 |
| Total funding | $20.6 million |
| Cost sharing | not required |
| Assistance Listings | 93.073 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

For an application to be considered, both Component A and B applications should have: A selected birth population and geographic study area that includes between 30,000 - 80,000 births annually; access to state National Electronic Disease Surveillance Systems for ascertainment of reportable infections; legal authority to share identifiable, individual-level data with CDC and other recipients. Component A should also have: legal access to a pre-existing, active birth defects surveillance system; legal access to data sources to ascertain liveborn control infants; a funding amount request that is less than $800,000 annually. Component B should also have legal access to data sources to ascertain stillbirths and a funding amount request that is less than $350,000 annually.

## What the grant funds

Birth defects affect about three percent of all births in the United States and are a leading cause of infant mortality, morbidity, and healthcare costs. Birth defects account for one in five infant deaths and contribute substantially to long-term disability. Although some causes of birth defects have been identified (e.g., genetics, medications, and environmental exposures), the causes of two-thirds of birth defects remain unknown. In 1996 Congress appropriated funds to develop the Centers for Birth Defects Research and Prevention (CBDRP). Beginning that fiscal year, CDC awarded cooperative agreements to up to 9 different centers. The two major collaborative activities of the centers have been case-control studies called the National Birth Defects Prevention Study (NBDPS), which collected data for deliveries between 1997 and 2011, and the Birth Defects Study To Evaluate Pregnancy exposureS (BD-STEPS), which began collecting data for deliveries in 2014 and is ongoing through 2023. To support research assessing risk factors for stillbirths (fetal deaths at 20 or more weeks gestation), a largely understudied pregnancy outcome, a case-control study of risk factors for stillbirth was added to BD-STEPS in 2015. This notice of funding opportunity will continue to support the capacity of BD-STEPS to identify novel epidemiologic and genetic risk factors for major, structural birth defects and for stillbirths, and to provide research findings that are intended to be translated into public health prevention messages, as warranted. Component A (BD-STEPS Core): Support the epidemiological and genetic birth defect-related research capabilities of BD-STEPS, with a focus on studying: (1) maternal chronic diseases and their treatments; (2) infectious disease in pregnancy; and (3) medications used during pregnancy. Component B (BD-STEPS Stillbirth): Support the exploration of modifiable risk factors for stillbirths. Component B recipients must apply for and receive concurrent Component A funding. New applicants and current BD-STEPS recipients are encouraged to apply for both components.

## Questions people ask

### Is RFA-DD-23-001 still open?

No. It closed on January 17, 2023. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.

### Who can apply for Birth Defects Study To Evaluate Pregnancy exposureS (BD-STEPS)?

Centers for Disease Control and Prevention - ERA accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Birth Defects Study To Evaluate Pregnancy exposureS (BD-STEPS)?

Closed January 17, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $1.2 million each. About $20.6 million in total across about 10 awards.

### Who has won Birth Defects and Developmental Disabilities - Prevention and Surveillance grants before?

The largest recipients over five fiscal years were The Johns Hopkins University, University of North Carolina at Chapel Hill, University of Texas at Austin. The program made 102 awards worth $94.9 million in that time.